#United States #Parkinson's Disease #Right Brain Bio #Pleasantville #RB-190

Right Brain Bio Joins the 3DEXPERIENCE Lab

Right Brain Bio, a clinical-stage biotechnology company dedicated to creating novel treatments for Parkinson's disease, has made headlines by being selected for the esteemed Dassault Systèmes 3DEXPERIENCE Lab. This prestigious recognition marks a significant step for the company as it aims to optimize its clinical trial process for its lead therapeutic candidate, RB-190.

The Importance of the 3DEXPERIENCE Lab

Joining the 3DEXPERIENCE Lab grants Right Brain Bio access to Dassault Systèmes' cutting-edge MEDIDATA clinical trial platform. This essential tool enables RBB to enhance its trial execution, facilitating quicker and more reliable results. Such capabilities are vital for the company as it ramps up efforts towards the Phase 2 development of RB-190.

Dasault Systèmes, recognized globally for its innovative engineering and scientific expertise, provides an ecosystem that merges digital capabilities across research, development, and clinical execution. This collaboration allows RBB to unify various aspects of its operations, optimizing the path for the successful development of its therapy.

Insights from Leadership

Jonathan Sackner-Bernstein, CEO and Founder of Right Brain Bio, emphasized the significance of this partnership at a critical juncture for the company: "The combination of Dassault Systèmes' renowned ecosystem and its MEDIDATA platform provides development resources to help us execute efficiently, generate high-quality data and position the company for strategic partnerships and future funding opportunities."

The motivation behind this partnership is to expedite the development of therapies that cater to the over 10 million individuals globally affected by Parkinson's disease. Right Brain Bio aims not just to treat symptoms but to address the underlying issues that contribute to the disease's progression.

A Revolutionary Approach to Therapy

The focal point of this venture is RB-190, a groundbreaking therapeutic agent engineered for Parkinson's treatment. RBB's innovative approach is geared towards reducing excessive dopamine production within dopaminergic neurons, a key factor in the progression of the disease. This repurposed and reformulated small molecule positions RB-190 as a potential first-in-class disease-modifying therapy.

Extensive research across nine preclinical models has shown promising outcomes, indicating that RB-190 not only alleviates symptoms but may also reverse certain pathological features of Parkinson's disease. By advancing towards Phase 2 clinical trials, RBB aims not only to validate these preliminary results but also to prepare for real-world applications of their therapy.

Conclusion

Right Brain Bio’s selection into the 3DEXPERIENCE Lab not only amplifies its visibility in the biotech space but also underscores its commitment to addressing a critical health issue. With an innovative product in RB-190 and the backing of a world-class platform like MEDIDATA, RBB is poised to make significant strides in the fight against Parkinson's disease, offering hope to millions worldwide.

The future initiatives and results from this collaboration remain highly anticipated as stakeholders eagerly await developments in the clinical trials. Right Brain Bio stands at the forefront of a crucial journey, with the potential to redefine the therapy landscape for Parkinson's disease.